DK1572745T3 - Antistof anti-humant NogoA og dets farmaceutiske anvendelse - Google Patents

Antistof anti-humant NogoA og dets farmaceutiske anvendelse

Info

Publication number: DK1572745T3
Authority: DK; Denmark
Prior art keywords: human; pharmaceutical use; binding molecule; human nogoa; antibody anti
Prior art date: 2002-12-10

Application number

DK03782350.7T

Other languages

English (en)

Inventor

Carmen Barske

Anis Khusro Mir

Thomas Oertle

Lisa Schnell

Martin E Schwab

Alessandra Vitaliti

Mauro Zurini

Original Assignee

Novartis Ag

Univ Zuerich

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-10

Filing date

2003-12-09

Publication date

2010-10-25

2003-12-09 Application filed by Novartis Ag, Univ Zuerich filed Critical Novartis Ag

2010-10-25 Application granted granted Critical

2010-10-25 Publication of DK1572745T3 publication Critical patent/DK1572745T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Immunology (AREA)
Psychiatry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Mycology (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Microbiology (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DK03782350.7T 2002-12-10 2003-12-09 Antistof anti-humant NogoA og dets farmaceutiske anvendelse DK1572745T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0228832.2A GB0228832D0 (en)	2002-12-10	2002-12-10	Organic compound
PCT/EP2003/013960 WO2004052932A2 (en)	2002-12-10	2003-12-09	Antibody (“11c7”) anti nogo a and its pharmaceutical use

Publications (1)

Publication Number	Publication Date
DK1572745T3 true DK1572745T3 (da)	2010-10-25

Family

ID=9949456

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03782350.7T DK1572745T3 (da)	2002-12-10	2003-12-09	Antistof anti-humant NogoA og dets farmaceutiske anvendelse

Country Status (25)

Country	Link
US (2)	US7785593B2 (da)
EP (1)	EP1572745B1 (da)
JP (1)	JP4504200B2 (da)
KR (1)	KR101215801B1 (da)
CN (1)	CN100384877C (da)
AT (1)	ATE475671T1 (da)
AU (1)	AU2003289998B2 (da)
BR (1)	BR0317161A (da)
CA (1)	CA2509068C (da)
CY (1)	CY1110848T1 (da)
DE (1)	DE60333585D1 (da)
DK (1)	DK1572745T3 (da)
EC (1)	ECSP055849A (da)
ES (1)	ES2349293T3 (da)
GB (1)	GB0228832D0 (da)
HK (1)	HK1084676A1 (da)
IL (1)	IL169018A (da)
MX (1)	MXPA05006265A (da)
NO (1)	NO20053304L (da)
PL (1)	PL210720B1 (da)
PT (1)	PT1572745E (da)
RU (1)	RU2350623C2 (da)
SI (1)	SI1572745T1 (da)
WO (1)	WO2004052932A2 (da)
ZA (1)	ZA200504522B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0228832D0 (en)	2002-12-10	2003-01-15	Novartis Ag	Organic compound
GB0321997D0 (en) *	2003-09-19	2003-10-22	Novartis Ag	Organic compound
JP4901480B2 (ja) *	2003-12-22	2012-03-21	グラクソグループリミテッド	神経疾患治療用の、ｎｏｇｏ−ａを中和する免疫グロブリン
BRPI0612734A2 (pt) *	2005-07-05	2010-11-30	Glaxo Group Ltd	anticorpo monoclonal, composição farmacêutica, métodos de promoção de brotamento axonal, e de produção de um anticorpo anti-nogo, e, uso de um anticorpo anti-nogo
GB0525662D0 (en)	2005-12-16	2006-01-25	Glaxo Group Ltd	Immunoglobulins
WO2009056509A1 (en)	2007-11-02	2009-05-07	Novartis Ag	Improved nogo-a binding molecules and pharmaceutical use thereof
JP2011527317A (ja) *	2008-07-11	2011-10-27	グラクソグループリミテッド	Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療
US8828390B2 (en)	2010-07-09	2014-09-09	Universitat Zurich	Uses of NOGO-A inhibitors and related methods
RU2014150265A (ru)	2012-07-05	2016-08-27	Глаксо Груп Лимитед	Оптимальный дозовый режим антитела против nogo-a в лечении бокового амиотрофического склероза
US9534044B2 (en) *	2013-02-28	2017-01-03	United Arab Emirates University	Alpha-synuclein antibodies and uses thereof
EP3632208A1 (en) *	2013-06-13	2020-04-08	Biomatrica, INC.	Cell stabilization
JP6966176B2 (ja)	2016-03-01	2021-11-10	イサムリサーチディベロップメントカンパニーオブザヘブルーユニバーシティオブエルサレムエルティーディー．	ヒトポリオウイルス受容体（ｐｖｒ）に特異的な抗体
WO2021079002A2 (en)	2019-10-24	2021-04-29	Novago Therapeutics Ag	Novel anti-nogo-a antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308573D0 (en)	1983-03-29	1983-05-05	British Nuclear Fuels Ltd	Filament impregnating/coating
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
ATE87659T1 (de)	1986-09-02	1993-04-15	Enzon Lab Inc	Bindungsmolekuele mit einzelpolypeptidkette.
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5180820A (en)	1989-08-30	1993-01-19	Barde Yves Alain	Brain-derived neurotrophic factor
ES2204890T3 (es)	1991-03-06	2004-05-01	Merck Patent Gmbh	Anticuerpos monoclonales humanizados.
DK1098972T3 (da)	1998-07-22	2011-01-03	Smithkline Beecham Ltd	Protein med lighed med neuroendokrinspecifikt protein samt cDNA kodende derfor
CA2350395C (en)	1998-11-06	2014-07-08	Martin E. Schwab	Nucleotide and protein sequences of nogo genes and methods based thereon
CU22921A1 (es) *	1999-11-16	2004-02-20	Centro Inmunologia Molecular	Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
GEP20063830B (en) *	2000-01-12	2006-05-25	Univ Yale	Nogo Receptor-Mediated Blockade of Axonal Growth
ES2437875T3 (es) *	2001-04-30	2014-01-14	Eli Lilly And Company	Anticuerpos humanizados que reconocen el péptido beta-amiloide
DE20110806U1 (de)	2001-06-29	2001-12-20	Jack Wolfskin Ausrüstung für Draussen GmbH, 65510 Idstein	Zelt
AR037456A1 (es) *	2001-11-30	2004-11-10	Biogen Inc	Anticuerpos contra proteinas quimiotacticas monocitarias
GB0228832D0 (en)	2002-12-10	2003-01-15	Novartis Ag	Organic compound
JP4901480B2 (ja)	2003-12-22	2012-03-21	グラクソグループリミテッド	神経疾患治療用の、ｎｏｇｏ−ａを中和する免疫グロブリン
US7596225B2 (en) *	2005-06-30	2009-09-29	Alcatl-Lucent Usa Inc.	Method for refreshing a pairwise master key

2002
- 2002-12-10 GB GBGB0228832.2A patent/GB0228832D0/en not_active Ceased
2003
- 2003-12-09 RU RU2005121669/13A patent/RU2350623C2/ru not_active IP Right Cessation
- 2003-12-09 AT AT03782350T patent/ATE475671T1/de active
- 2003-12-09 KR KR1020057010410A patent/KR101215801B1/ko not_active IP Right Cessation
- 2003-12-09 PT PT03782350T patent/PT1572745E/pt unknown
- 2003-12-09 MX MXPA05006265A patent/MXPA05006265A/es active IP Right Grant
- 2003-12-09 CN CNB2003801096228A patent/CN100384877C/zh not_active Expired - Fee Related
- 2003-12-09 EP EP03782350A patent/EP1572745B1/en not_active Expired - Lifetime
- 2003-12-09 DK DK03782350.7T patent/DK1572745T3/da active
- 2003-12-09 ES ES03782350T patent/ES2349293T3/es not_active Expired - Lifetime
- 2003-12-09 DE DE60333585T patent/DE60333585D1/de not_active Expired - Lifetime
- 2003-12-09 PL PL377506A patent/PL210720B1/pl unknown
- 2003-12-09 BR BR0317161-2A patent/BR0317161A/pt active Search and Examination
- 2003-12-09 JP JP2004558049A patent/JP4504200B2/ja not_active Expired - Fee Related
- 2003-12-09 CA CA2509068A patent/CA2509068C/en not_active Expired - Fee Related
- 2003-12-09 US US10/538,201 patent/US7785593B2/en not_active Expired - Fee Related
- 2003-12-09 SI SI200331887T patent/SI1572745T1/sl unknown
- 2003-12-09 WO PCT/EP2003/013960 patent/WO2004052932A2/en active Application Filing
- 2003-12-09 AU AU2003289998A patent/AU2003289998B2/en not_active Ceased
2005
- 2005-06-06 IL IL169018A patent/IL169018A/en not_active IP Right Cessation
- 2005-06-10 EC EC2005005849A patent/ECSP055849A/es unknown
- 2005-07-06 NO NO20053304A patent/NO20053304L/no not_active Application Discontinuation
2006
- 2006-02-08 ZA ZA200504522A patent/ZA200504522B/en unknown
- 2006-02-24 HK HK06102543.2A patent/HK1084676A1/xx not_active IP Right Cessation
2010
- 2010-06-18 US US12/819,060 patent/US8535666B2/en not_active Expired - Fee Related
- 2010-10-19 CY CY20101100934T patent/CY1110848T1/el unknown

Also Published As

Publication number	Publication date
CA2509068A1 (en)	2004-06-24
HK1084676A1 (en)	2006-08-04
MXPA05006265A (es)	2005-12-05
CN1747971A (zh)	2006-03-15
ECSP055849A (es)	2005-09-20
RU2005121669A (ru)	2007-01-20
PT1572745E (pt)	2010-10-21
WO2004052932A2 (en)	2004-06-24
AU2003289998A1 (en)	2004-06-30
NO20053304D0 (no)	2005-07-06
CA2509068C (en)	2012-02-07
US8535666B2 (en)	2013-09-17
CY1110848T1 (el)	2015-06-10
WO2004052932A3 (en)	2004-10-21
IL169018A (en)	2012-07-31
ES2349293T3 (es)	2010-12-29
CN100384877C (zh)	2008-04-30
SI1572745T1 (sl)	2010-12-31
DE60333585D1 (de)	2010-09-09
RU2350623C2 (ru)	2009-03-27
EP1572745B1 (en)	2010-07-28
AU2003289998B2 (en)	2008-02-14
US20110059110A1 (en)	2011-03-10
PL210720B1 (pl)	2012-02-29
PL377506A1 (pl)	2006-02-06
ATE475671T1 (de)	2010-08-15
KR101215801B1 (ko)	2012-12-26
BR0317161A (pt)	2005-11-01
JP2006523087A (ja)	2006-10-12
NO20053304L (no)	2005-09-07
US20060183678A1 (en)	2006-08-17
ZA200504522B (en)	2006-03-29
KR20050095768A (ko)	2005-09-30
JP4504200B2 (ja)	2010-07-14
GB0228832D0 (en)	2003-01-15
EP1572745A2 (en)	2005-09-14
US7785593B2 (en)	2010-08-31

Publication	Publication Date	Title
HK1084676A1 (en)	2006-08-04	Antibody anti human nogo a and its pharmaceutical use
ECSP056263A (es)	2006-04-19	Anticuerpos humanizados que reconocen el péptido beta amiloideo
CY1120252T1 (el)	2019-07-10	Μορια δεσμευσης αντιγονου με αυξημενη συγγενεια προσδεσης στον υποδοχεα fc και λειτουργια τελεστη
DE60130538D1 (de)	2007-10-31	Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
CY1117387T1 (el)	2017-04-26	ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
WO2006083964A3 (en)	2009-04-30	Modified fusion molecules for treatment of allergic disease
WO2003034903A3 (en)	2003-10-30	Psma antibodies and protein multimers
TW200500377A (en)	2005-01-01	Method of humanizing immune system molecules
EA200801509A1 (ru)	2008-12-30	Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
ATE455127T1 (de)	2010-01-15	Humane anti-humane cd3-bindungsmoleküle
DE60224291D1 (de)	2008-02-07	System zur antikörperexpression und- synthese
BRPI0715660B8 (pt)	2021-05-25	anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal
WO2007039256A3 (de)	2007-07-05	Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
TNSN06085A1 (en)	2007-10-03	Nogo-a binding with enhanced affinity and pharmaceutical use thereof
ATE459004T1 (de)	2010-03-15	Ligand für den formylpeptidrezeptorähnlichen- 2 (fprl2) g protein gekoppelten rezeptor und dessen anwendung
TW200635946A (en)	2006-10-16	Binding proteins specific for human matriptase
ATE370235T1 (de)	2007-09-15	Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden
EP1411962A4 (en)	2005-02-02	MONOCLONAL ANTIBODY TREATMENT OF PANCREATIC CANCER
BRPI0407031A (pt)	2006-01-17	Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
ATE312921T1 (de)	2005-12-15	Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
WO2004032832A3 (en)	2004-10-21	Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment
Cai et al.	2007	Identification of a cysteine-histidine thioether bridge bond in functional units d, e and f of β</inf> c<//inf>-haemocyanin of the gastropod Helix pomatia